Compared with control subjects having the major allele, patients with at least one C allele at EZH2 rs6950683 showed no significant differences between EZH2 genotypic frequencies and clinicopathological variables (Table 3); however, patients with at least one G allele at EZH2 rs2302427 showed a 0.418-fold (95% CI: 0.220–0.794) decrease in invasive tumor stage (Table 4). The gene discussed is EZH2; the disease is neoplasm.